Drug pricing white paper allays pharma patent fears, but innovators should remain vigilant
A recent report from the US president’s executive office on reducing drug prices makes reassuring reading for innovators concerned about the future of pharmaceutical patents under the Trump administration. In contrast to comments previously made by…
To read more
Register for limited access
Register to receive our newsletter and gain limited access to subscriber content.
Subscribe to unlock unlimited access
Get news, unique commentary, expert analysis and essential resources from the IAM experts.